Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL838769 | 0.98 | GAA (0.41) | GAALMNAMAPTALDH1A1TDP1 | |
| SCHEMBL838116 | 0.83 | EGFR (0.38) | LMNAALDH1A1TDP1MAPK1CYP1A2 | |
| SCHEMBL1144086 | 0.83 | GAA (0.44) | GAALMNAMAPTALDH1A1TDP1 | |
| Bromide SCHEMBL20984925 | 0.80 | EGFR (0.37) | LMNAALDH1A1TDP1CYP1A2EGFR | |
| Hydrochloric Acid SCHEMBL20984617 | 0.80 | EGFR (0.37) | LMNAMAPTALDH1A1TDP1KMT2A | |
| Hydrochloric Acid SCHEMBL839849 | 0.80 | GAA (0.42) | GAALMNAMAPTALDH1A1TDP1 | |
| Bromide SCHEMBL20984793 | 0.80 | GAA (0.42) | GAALMNAMAPTALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL21357474 | 0.78 | GAA (0.41) | GAALMNAMAPTALDH1A1TDP1 | |
| SCHEMBL11883002 | 0.74 | GAA (0.37) | GAALMNATDP1MEN1KMT2A | |
| SCHEMBL1997895 | 0.73 | GAA (0.59) | GAALMNAMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914277-B | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | 上海瑛派药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| CN-110914277-A | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | 上海瑛派药业有限公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019011228-A1 | IMIDAZO[1,2-B]PYRIMIDO[4,5-D]PYRIDAZIN-5(6H)-ONE COMPOUND AND USE THEREOF | 上海瑛派药业有限公司 | 2019-01-17 | — | — | WO | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071608-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| CN-102171213-A | Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity | ASTRAZENECA AB | 2011-08-31 | — | — | CN | disclosed |
| WO-2010116176-A1 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | WEE1, WEE2, CCNE1 | GAA 1782/4885LMNA 3641/4885MAPT 4290/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | GAA 63/4885LMNA 3530/4885MAPT 3944/4885 |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | WEE1, WEE2, CCNE1 | GAA 1782/4885LMNA 3641/4885MAPT 4290/4885 |
| US-20100261733-A1 | THERAPEUTIC AGENTS 927 | GCK, GCKR, GALK1 | GAA 164/4885LMNA 3473/4885MAPT 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.